Evaluation of the Microbiome in Multiple Sclerosis
Multiple Sclerosis
About this trial
This is an interventional basic science trial for Multiple Sclerosis
Eligibility Criteria
Inclusion Criteria: Age between 18 and 60 years inclusive. Have diagnosis of Multiple Sclerosis (relapsing remitting or secondary progressive for the MS cohort) or be a healthy individual living in the same household (non-MS for the healthy control cohort) No antibiotics, or colon cleanses/bowel preparation in the previous 2 weeks. Written informed consent Exclusion Criteria: Known to have swallowing disorders Known disease which, in the investigator's opinion, would lead to intestinal stricture or obstruction with a risk of capsule non-excretion (particular diseases which would be assessed on a case-by-case basis would include, achalasia, eosinophilic esophagitis, diverticulitis, Crohn's disease, Ulcerative colitis, cancer diagnosis or treatment within the past year, or previous oesophageal, gastric, small intestinal, or colonic surgery. 3) Appendectomy or cholecystectomy more than 3 months prior to enrolment are acceptable). The main deciding factor would be history of obstructive symptoms in the previous 3 months prior to entry. Use of any medications in the previous week that could substantially alter gastrointestinal motor function (e.g., opioids, prokinetics, anticholinergics, laxatives), or acidity (PPI, H2RA); for both groups. < 2 bowel movements per week (for both groups). Risk or suspect of being pregnant
Sites / Locations
- University of CalgaryRecruiting
Arms of the Study
Arm 1
Experimental
Single Arm
Participant swallows and retrieves capsule in stool. Intestinal fluid samples collected by SIMBA capsules from the MS and HC participants, along with a fecal and blood samples, will be used for gut microbiome, viral and metabolomic analysis.